Umbilical cord serum levels of thromboxane B2 in term infants of women who participated in a Placebo-Controlled trial of low-dose aspirin

2000 ◽  
Vol 9 (4) ◽  
pp. 209-215
Author(s):  
C. Richard Parker ◽  
John C. Hauth ◽  
Robert L. Goldenberg ◽  
Rachel L. Copper ◽  
Mary B. Dubard
Keyword(s):  
Umbilical Cord ◽  
Low Dose ◽  
Controlled Trial ◽  
Serum Levels ◽  
Thromboxane B2 ◽  
Term Infants ◽  
Cord Serum ◽  
Dose Aspirin ◽  
Low Dose Aspirin

The Safety of Low-Dose Aspirin on the Mode of Delivery: Secondary Analysis of the Effect of Aspirin in Gestation and Reproduction Randomized Controlled Trial

2020 ◽  
Author(s):  
Allison A. Eubanks ◽  
Carrie J. Nobles ◽  
Sunni L. Mumford ◽  
Keewan Kim ◽  
Micah J. Hill ◽  
...  
Keyword(s):  
Vaginal Delivery ◽  
Live Birth ◽  
Low Dose ◽  
Controlled Trial ◽  
Mode Of Delivery ◽  
Secondary Analysis ◽  
Clinical Effects ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Intent To Treat

Objective This study aimed to examine whether prenatal low-dose aspirin (LDA) therapy affects risk of cesarean versus vaginal delivery. Study Design This study is a secondary analysis of the randomized clinical effects of aspirin in gestation and reproduction (EAGeR) trial. Women received 81-mg daily aspirin or placebo from preconception to 36 weeks of gestation. Mode of delivery and obstetric complications were abstracted from records. Log-binomial regression models estimated relative risk (RR) of cesarean versus vaginal delivery. Data were analyzed among the total preconception cohort, as well as restricted to women who had a live birth. Results Among 1,228 women, 597 had a live birth. In the intent-to-treat analysis, preconception-initiated LDA was not associated with risk of cesarean (RR = 1.02; 95% confidence interval [CI]: 0.98–1.07) compared with placebo. Findings were similar in just women with a live birth and when accounting prior cesarean delivery and parity. Conclusion Preconception-initiated daily LDA was not associated with mode of delivery among women with one to two prior losses. Key Points

Low-Dose Aspirin for the Prevention and Treatment of Preeclampsia

2021 ◽  
pp. 7-12
Author(s):  
Danielle M. Panelli ◽  
Deirdre J. Lyell
Keyword(s):  
Lower Risk ◽  
Low Dose ◽  
Controlled Trial ◽  
Entire Cohort ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Prevention And Treatment ◽  
Double Blinded ◽  
The Impact ◽  
To Receive

“CLASP: A Randomized Trial of Low-Dose Aspirin for the Prevention and Treatment of Preeclampsia Among 9364 Pregnant Women” was a double-blinded, placebo-controlled trial that evaluated the impact of antenatal aspirin administration on development of preeclampsia and intrauterine growth restriction (IUGR). A total of 9364 women either at risk for preeclampsia or currently experiencing preeclampsia or IUGR were enrolled between 12 and 32 weeks and randomized to receive 60mg aspirin daily or placebo. While a nonsignificant 12% reduction in the odds of preeclampsia was found among the entire cohort, the reduction in preeclampsia with aspirin use was more pronounced for those who began prophylaxis prior to 20 weeks (22% reduction, p = 0.06). There was also a lower risk of preterm birth before 37 weeks in those who received aspirin at any time (19.7% vs. 22.2%, p = 0.003) but no difference in IUGR infants. In conclusion, 60mg aspirin daily did not significantly reduce the risk of preeclampsia or IUGR among the women included in this study.

Sign in / Sign up

Export Citation Format

Share Document